Cadence Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History

Cadence Capital Management’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-7,438	Closed	-$553K	–	639
2016 Q2	$553K	Buy	+7,438	New	+$552K	0.04%	429
2015 Q4	–	Sell	-17,841	Closed	-$953K	–	631
2015 Q3	$953K	Sell	17,841 -39,830	-69%	-$2.42M	0.07%	303
2015 Q2	$3.63M	Buy	+57,671	New	+$3.15M	0.2%	133

Other funds holding LGND

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DMK

David M. Knott $275M AUM 59.23% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ORI

Oak Ridge Investments Chicago, Illinois $1.51B AUM 37.25% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

Cadence Capital Management's LGND Position: Q3 2016 in Review

Cadence Capital Management sold out of Ligand Pharmaceuticals (LGND) in Q3 2016, closing a stake of 7,438 shares — an estimated $553K sold.

Cadence Capital Management first reported a position in LGND in Q2 2015 and held it in 3 quarters. The position peaked at $3.63M in Q2 2015. 259 funds tracked by Wall St. Rank hold LGND as of Q3 2016.

Cadence Capital Management reported no remaining Ligand Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
Cadence Capital Management sold 7,438 Ligand Pharmaceuticals shares in Q3 2016, an estimated $553K.
Cadence Capital Management first reported a position in Ligand Pharmaceuticals in Q2 2015 and held it in 3 quarters.
Cadence Capital Management's Ligand Pharmaceuticals position peaked at $3.63M in Q2 2015.
259 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2016.

Based on Cadence Capital Management's 13F filing for Q3 2016, filed 10 Nov 2016.